Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Suloctidil”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1989

Suloctidil increases the rat brain cortex microvascular regeneration after a lesion.

A "cavity" lesion made by aspiration in the rat occipital cortex induces a parenchymal and a vascular reaction in its vicinity. The first was mainly characterized by cellular necrosis and gliosis, the second by an increase of the vascular network. In vehicle treated rats, a 50% significant increase of the vascular network was observed around the cavity 4 days after the lesion, in comparison to the uninjured contralateral cortex. The effects of a vasoactive substance, suloctidil, on the vascular reaction was studied in the brain cortex. A single oral dose of suloctidil (30 mg/kg; 2 hours before the sacrifice) gave the same effect as the vehicle group. After 8 days of suloctidil oral administration (30 mg/kg; twice daily: 4 days before lesion and 4 days after) a significant increase (123%) of the vascular network was observed around the cavity. The hypothetical ways by which a chronic treatment of suloctidil induces this increase of the neovascularization observed after cortical lesion are discussed.

Animals↗
PubMed1984

Effect of suloctidil on platelet function in patients with shortened platelet survival time.

The effect of suloctidil (600 mg/day) on platelet survival time (PST) and plasma and urine betathromboglobulin (BTG) was studied in a double-blind, placebo-controlled six-week crossover trial in 13 patients with shortened PST (less than 110 hrs, exponential model). Mean PST after suloctidil (110.6 hrs) was significantly higher than in the placebo phase (94.5 hrs) (p = 0.04). Mean plasma BTG was significantly lower during the suloctidil phase (42.8 ng/ml) compared with the placebo phase (65.8 ng/ml) (p = 0.02), but there was no significant difference in urine BTG. These results suggest that suloctidil provides a platelet protective effect and therefore may be of benefit in reducing the frequency of platelet mediated thromboembolic events.

Blood Platelets↗
PubMedDate not supplied

Controlled trial of suloctidil in intermittent claudication.

Forty-five patients with intermittent claudication were first treated with placebo tablets for 3 months and then randomly allocated to double-blind therapy with either suloctidil or placebo for 6 months. Walking distance improved significantly in both groups during the 3 months of placebo treatment. During the 6 months of double-blind treatment with a further significant improvement occurred only in the placebo group when all patients were analyzed. However, when patients who stopped for reasons unrelated to claudication such as angina and exhaustion during repeated walking tests were eliminated, only suloctidil-treated patients improved significantly. The evolution of leg flow and distal pressure was similar in the two treatment groups whether all legs or only legs with abnormal flow and pressure values were considered. By contrast, when the analysis was limited to legs with claudication pain, a significant improvement occurred only in the suloctidil-treated group. These findings suggest that suloctidil may improve the claudication symptoms of patients with chronic arterial obstructive disease and in particular the perfusion of legs experiencing claudication pain. However, the clinical significance of this improvement appears limited.

Clinical Trials as Topic↗
PubMed1981

Inhibition of Ca-movement and mechanical movement in rabbit taenia coli by a smooth muscle relaxant (suloctidil).

A smooth muscle relaxant (suloctidil) relaxed a contractile response of taenia coli to acetylcholine and noncompetitively depressed a dose response curve of Cacl2 Ca-uptake by the microsomal fraction was inhibited by suloctidil. Its noncompetitive antiacetylcholine activity and inhibitory action on Ca-uptake were not influenced by an increase of external Ca-concentration. Ca-release from the Ca-incorporated microsomal fraction was not significantly influenced by suloctidil. These results suggest that suloctidil inhibit Ca-influx noncompetitively, thus inducing smooth muscle relaxation.

Animals↗
PubMed1988

Effects of the antithrombotic drug suloctidil on low density lipoprotein processing and cholesterol metabolism in cultured human fibroblasts.

Human foetal lung fibroblasts were pretreated for 24 h with the antithrombotic drug, suloctidil (1 to 10 mumol/l), which induced a dose-dependent increase in LDL binding, uptake and degradation. At 10 mumol/l suloctidil, the respective increases in these parameters were 40%, 80% and 50%. The same treatment also resulted in increases of 1.5 to 2-fold in the synthesis of sterols, fatty acids and triacylglycerols from sodium acetate. In contrast, the esterification of cholesterol with oleic acid was specifically decreased by 35% by 24 h pretreatment of fibroblasts with 10 mumol/l suloctidil. A similar decrease of cholesterol esterification was observed in cholesterol-laden fibroblasts. It is suggested that these effects of suloctidil on LDL processing and cholesterol metabolism are related to the amphiphilic characteristics of the drug and to its calcium-blocking properties.

Cell Line↗
PubMed1985

Studies of suloctidil in experimental thrombosis in baboons.

Suloctidil has been evaluated in the baboon for its antithrombotic efficacy using models of both acute and chronic arterial thrombogenesis. Acute thrombus formation was initiated by Dacron vascular grafts inserted as extension segments into chronic arteriovenous shunts. 111In-platelet deposition was measured by scintillation camera imaging for one hour. The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies. Moreover, concurrent heparin anticoagulation did not affect 111In-platelet deposition compared with control data. In contrast, ticlopidine (20 mg/kg/d) significantly decreased platelet deposition that was reduced further by the addition of heparin. Chronic arterial-thromboembolism was initiated by segments of polyurethane (Biomer) cannula introduced into chronic arteriovenous shunts. Thrombus formation by the polyurethane cannula was measured as 111In-platelet turnover (corrected for removal of senescent platelets). Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement). In contrast, dipyridamole (10 mg/kg/d) and sulfinpyrazone (100 mg/kg/d) completely interrupted cannula platelet consumption. We conclude that suloctidil probably has little or no effect on platelet-dependent thrombus formation.

Acute Disease↗
PubMed1983

[Effect of suloctidil on the reduced evoked potentials in brain slices in low glucose perfusate].

Effects of suloctidil [erythro-1-(4-isopropylthiophenyl)-2-n-octylaminopropanol] on reduced evoked potentials in low glucose perfusate were studied using guinea-pig prepyriform cortex in vitro. The amplitude of evoked potential to paired electrical stimulation of the olfactory tract in cerebral slices was consistently and reversibly suppressed by the perfusion with low glucose (3 mM)-Krebs-Ringer's solution. The amplitude reduction after 10 min exposure to the perfusate was fairly reproducible in the same preparation. The amplitude reduction was always accompanied with significant facilitation of "postactivation potentiation", estimated from the size of the first and second response to paired stimulation. Perfusion of brain slices with low glucose Krebs-Ringer's solution containing 10(-7)-10(-6) g/ml suloctidil for 10 min, however, effectively prevented the reduction of amplitude of evoked potentials to below 30-50% of the control value. The facilitation of postactivation potentiation under the low glucose condition was also suppressed by the drug. Dihydroergotoxin, 3 X 10(-6) g/ml, also showed a comparable effect as 10(-6) g/ml suloctidil. These data suggest that suloctidil possesses a brain energy economizing effect such as activation of oxygen, glucose uptake or production of high energy substance.

Animals↗
PubMed1976

Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo.

Forty-five patients suffering from intermittent claudication were admitted to a double-blind non-crossover study. Three groups were constituted at random and treated for 2 months with either 100 mg suloctidil t.i.d. or 1.5 mg dihydroergotoxine methylate t.i.d. or placebo. From the results of measurements of pain-free walking distance and venous occlusion plethysmography recordings, suloctidil was shown to be active and significantly superior to dehydroergotoxine and placebo: in the two latter groups a decrease in calf blood perfusion after 2 months was also noted. The physician's overall assessment of response to treatment showed that suloctidil and dihydroergotoxine were significantly superior to placebo, and that suloctidil was significantly better than dihydroergotoxine.

Aged↗
PubMed1985

Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.

A double-blind, parallel group, placebo-controlled study was carried out in 30 elderly patients with moderate to severe mental deterioration to assess the effect of suloctidil on their mental condition. A battery of clinical and psychometric evaluations failed to demonstrate any significant differences between the two groups at the end of a 6-month treatment period during which patients received either 200 mg suloctidil or placebo 3-times daily. However, further analysis of the results showed that in the sub-group of patients with moderate mental deterioration on entry, suloctidil treatment produced significant improvement from baseline in the Rey 15 words test and the results were significantly different from those in patients with severe mental deterioration. No consistent changes were observed in the placebo group.

Age Factors↗
PubMed1979

Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients.

1-(4-Isopropylthiophenyl)-2-n-octylaminopropanol (suloctidil, Sulocton), a drug introduced into clinical practice for the treatment of cerebral and peripheral vascular insufficiency and its complications, has been shown to decrease blood hyperviscosity after long-term treatment in diabetic patients. Suloctidil was particularly effective in lowering measured blood viscosity at high shear rate (230 s-1). At low shear rate (0.77 s-1) a decreasing effect was also observed but reached a statistically significant level only after one month. Since neither total plasma fibrinogen levels nor red blood cell deformability were modified by suloctidil treatment, its lowering effect on blood hyperviscosity could be due to a hitherto unrecognized mechansim of action.

Adult↗
PubMedDate not supplied

[Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].

Suloctidil, a new vasoactive drug, shows certain properties which make it particularly suitable for using in migraine. The author administered Suloctidil in daily doses of 600 mg to 12 patients with migraine during 6 weeks. In 9 cases good results were obtained. Although further investigations are necessary, it seems already now that Suloctidil will enrich the armamentarium of antimigrainous drugs.

Adult↗
PubMed1982

Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).

A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.

Adult↗
PubMed1983

Activation of platelets and of fibrinolysis by venous occlusion in healthy volunteers and influence of suloctidil in comparison with placebo.

The effect of venous occlusion on blood fibrinolytic activity and platelet activation was studied in 10 normal human volunteers. The procedure was used as a model to study the pharmacological effects of 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol (suloctidil, Sulocton) in a double-blind cross-over trial comparing suloctidil 200 mg three times per day versus identical placebo, each given for one week at random, after an initial one-week placebo run-in; blood sampling was done at the end of each period. Statistically significant changes in plasminogen, alpha 2-anti-plasmin, fibrinogen and antithrombin-III were consistently obtained on each occasion and could be ascribed to local haemoconcentration while a much higher increase of plasminogen activator activity occurred. The influence of venous occlusion on plasma beta-thromboglobulin and platelet factor-4 levels was found to be less consistent and under the trial conditions no obvious difference between the regimens studied could be objectified. On the contrary platelet aggregation by collagen was significantly reduced at the end of the suloctidil period.

Adult↗
PubMed1987

An experimental evaluation of the efficacy of suloctidil in the treatment of primary degenerative dementia.

A double-blind, placebo-controlled randomized design was employed to test the efficacy and optimal dosage of Suloctidil in the treatment of primary degenerative dementia (PDD i.e., Alzheimer's disease). Initially, 30 geriatric patients with a diagnosis of PDD were matched for age, education, and handedness, and randomly assigned to one of three groups: (a) 600 mg. Suloctidil daily; (b) 450 mg. Suloctidil daily; (c) or placebo, for 12 weeks. All patients were administered individually a brief neuropsychological battery at pretreatment and at 12-week posttreatment. The tests were the Boston Naming Test, the Thurstone Word Fluency Test, the Trail Making Test, and the Grooved Pegboard. While there was differential attrition across the three groups, the results of the Boston Naming Test suggest a medication-dosage effect.

Clinical Trial↗
PubMed1984

Conformational analysis of suloctidil and derivatives inserted in lipid layers.

Interaction between suloctidil (CP 556 S) and lipids (phosphatidylcholine, phosphatidylserine) is studied using a new conformational analysis procedure. This analysis is extended to two compounds related to suloctidil but bearing no protonable group (CP 894 S) or of different hydrophobicity (CP 1136 S). It gives a molecular description of the mode of insertion of the drugs into the lipid layer. The influence of the calculated lipid-drug interaction and area occupied per drug molecule in the lipid layer is tentatively related to the effect on the lipid dynamics. For a given conformer, an effect on the lipid dynamics is expected only if (a) the area occupied per conformer is similar to that of the lipid and/or (b) the drug-lipid interaction energy is equal or superior to that of the lipid-lipid interaction. These predictions are analyzed in terms of the available experimental data.

Lipids↗
PubMed1988

Suloctidil-induced hepatotoxicity.

Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders. Hepatotoxicity has to date been reported exclusively in the European literature, and the few available histologic descriptions have been reported in the French language. We report a case of suloctidil-induced hepatotoxicity documented by serum liver biochemical tests and liver biopsy. Histologic features included focal necrosis of hepatocytes, mild hyperplasia of Kupffer cells, and other features suggestive of mild acute hepatitis.

Aged↗
PubMed1983

Suloctidil therapy in migraine: an open pilot study.

An open pilot study was carried out in 27 patients with severe and frequent migraine attacks who had failed to respond adequately to other drug therapy, to assess the effectiveness and tolerance of prophylactic treatment with suloctidil. Patients received 600 mg suloctidil daily for 6 weeks. Response, assessed on the reduction in frequency of attacks, was considered as good in 7 patients and as significant improvement in 11 patients. Treatment was rated as of doubtful value or as ineffective in the other 9 patients. One patient stopped treatment because of adverse reactions and 10 others reported mild side-effects.

Adult↗
PubMedDate not supplied

[The effect of suloctidil and acetylsalicylic acid on eicosanoid synthesis in human platelets].

The study aimed at comparing an effect of suloctidil and acetylsalicylic acid on malonyldialdehyde levels resulting from the arachidonic acid metabolism in blood platelets. It was shown that inhibitory effect of suloctidil is more potent than that of acetylsalicylic acid. Therefore the first is more inhibitor of an enzymatic metabolism of arachidonate in blood platelets than the latter.

Adult↗